Moderna 2022 Priorities and Capital Allocation
Moderna's therapeutics
Pipeline Highlights
Immuno-oncology
•
PCV Phase 1 ongoing; Phase 2 fully enrolled,
data expected in 4Q 2022
KRAS Phase 1 ongoing; evaluating next steps
•
for the program
•
Triplet, IL-12 ongoing in Phase 1
•
Modality
Systemic
Checkpoint vaccine in preclinical
Cardiovascular
⚫ VEGF moving to Phase 2b (AstraZeneca)
.
Relaxin in preclinical
Autoimmune
•
IL-2 Phase 1 ongoing
.
PD-L1 in preclinical
Rare diseases
.
PA Phase 1 cohort fully enrolled; enrolling
1000
ID #
Preclinical
development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights
Worldwide
Program
IL-2
Autoimmune disorders
mRNA-6231
secreted & cell Relaxin
surface
Heart failure
mRNA-0184
therapeutics
PD-L1
Autoimmune hepatitis
mRNA-6981
Personalized cancer vaccine
(PCV)
mRNA-4157
Cancer
vaccines
KRAS vaccine
mRNA-4671
Checkpoint vaccine
mRNA-4359
Intratumoral
Immuno-
oncology
OX40L/IL-23/IL-36y (Triplet)
mRNA-2752
Solid tumors/lymphoma
IL-12
MEDI1191
Solid tumors
Localized
VEGF-A
Regenerative
Myocardial ischemia
AZD8601
Therapeutics
Propionic acidemia (PA)
mRNA-3927
Methylmalonic acidemia (MMA) mRNA-3705
Systemic
Intracellular
Therapeutics
Glycogen storage disease type
la (GSD1a)
mRNA-3745
Open IND
Phenylketonuria (PKU)
mRNA-3283
Crigler-Najjar syndrome type 1
(CN-1)
mRNA-3351
Cystic fibrosis (CF)
VXC-522
additional cohorts
MMA Phase 1 cohort fully enrolled; enrolling
additional cohorts
GSD1a open IND
Inhaled
Pulmonary
Therapeutics
•
PKU, CN-1 and CF in preclinical
Slide 26
Worldwide
Worldwide
50-50 global profit
sharing with Merck
Worldwide
Worldwide
Worldwide
50-50 U.S. profit sharing:
AZ to pay royalties on ex-
U.S. sales
AZ to pay milestones and
royalties
Worldwide
Worldwide
Worldwide
Worldwide
Provided to ILCM free of
charge
Vertex to pay milestones
and royalties
modernaView entire presentation